To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of prescribing ivermectin for reducing the (a) transmission or (b) severity of covid-19.
This answer is the replacement for a previous holding answer.
25 January 2021
The Therapeutics Taskforce is continuing to monitor any new, high quality evidence on COVID-19 therapeutics and has been following recent findings on ivermectin.
The Department has monitored a collection of small studies which have now completed and provided some positive signals on the use of ivermectin as a treatment for COVID-19. This is a promising step. However, larger-scale studies are still needed to confirm the effectiveness and safety of this treatment. The Therapeutics Taskforce is aware that several more studies into ivermectin are set to conclude in the next few months and will continue to monitor these ongoing trials to assess the evidence available on whether ivermectin reduces transmission and/or severity of COVID-19. The Department and its arm’s length bodies are prepared to act rapidly should any trial readouts prove positive at a greater scale.